Clinical Trial Update: Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China

View source ↗

Summary

An observational clinical trial evaluating SIR-Spheres therapy for hepatocellular carcinoma in China, currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• SIR-Spheres Therapy (Yttrium-90 resin microspheres)

Snippet

Sponsor: GrandPharma (China) Co., Ltd. | Conditions: Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Non-Resectable | Status: ENROLLING_BY_INVITATION